David Nierengarten

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded Myokardia from Outperform to Neutral and raised the price target from $127 to $225. Wells Fargo...

AnaptysBio Inc (NASDAQ: ANAB) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-severe generalized pustular psoriasis. The Analyst Wedbush analyst David Nierengarten reiterated an...

Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansions and earlier-stage pipeline efforts, according to Wedbush. The Analyst Wedbush’s David...

Bluebird bio Inc (NASDAQ: BLUE) held its Analyst Day in New York last week, and at least one analyst came away less bullish on the stock. The Analyst Wedbush's David Nierengarten downgraded bluebird bio from Outperform to Neutral and reduced his price target from $166 to $131. The Thesis The...

Stemline Therapeutics Inc (NASDAQ: STML) reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago. The Analyst Wedbush analyst David Nierengarten downgraded Stemline from Outperform to Neutral and maintained an $18 price...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares, which suffered a setback in late February following the release of the FDA's briefing document and panel vote on its multiple myeloma treatment candidate Selinexor, were seeing upward momentum on double their average volume Friday. What...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are poised to extend their losses to the fifth straight session, with the most recent trigger being the adcom meeting on its multiple myeloma drug. The Analysts Wedbush analyst David Nierengarten maintained an Outperform rating on KaryoPharm...

Applied Genetic Technologies Corp (NASDAQ: AGTC), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis clinical study. The company also confirmed Biogen Inc (NASDAQ: BIIB) terminated...

GlaxoSmithKline plc (NYSE: GSK) on Monday announceda $5.1 billion deal to acquire Tesaro Inc (NASDAQ: TSRO) in a bid to augment its oncology franchise. The Analyst Wedbush analyst David Nierengarten downgraded Tesaro from Outperform to Neutral and upped the price target from $60 to $75. The Thesis...

Magenta Therapeutics Inc (NASDAQ: MGTA), which made an initial public offering last month, is operating in an area largely overlooked by drug developers, according to Wedbush. The Analyst Analyst David Nierengarten initiated coverage of Magenta with an Outperform rating and $22 price...

Epizyme Inc (NASDAQ: EPZM)'s announcement that the FDA was placing a partial hold on its lead cancer candidate tazemetostat has "minimal" long-term consequences, a Wedbush analyst said Tuesday.   The Analyst Analyst David Nierengarten maintained an Outperform rating on...

Spark Therapeutics Inc (NASDAQ: ONCE), a gene therapy company that treats orphan diseases including a rare retinal disease that can lead to blindness, said in early January it will price its therapy at $850,000 for a one-time treatment of both eyes. The Analyst Wedbush's David Nierengarten...

Shares of Endocyte, Inc. (NASDAQ: ECYT) were trading higher by more than 60 percent Tuesday afternoon at $5.82 on top of Monday's monster triple-digit-percentage return gain, but some analysts see even more upside. Wedbush's David Nierengarten upgraded Endocyte's stock rating Neutral to Outperform...